nipocalimab-aahu

FDA Drug Profile — IMAAVY

nipocalimab-aahu is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including IMAAVY. Available dosage form: injection, solution, concentrate.

Drug details

Generic Name
nipocalimab-aahu
Brand Names
IMAAVY
Application Number
BLA761430
Sponsor
Janssen Biotech, Inc.
NDC Codes
4
Dosage Forms
INJECTION, SOLUTION, CONCENTRATE
Routes
INTRAVENOUS
Active Ingredients
NIPOCALIMAB

Indications and Usage

1 INDICATIONS AND USAGE IMAAVY is a neonatal Fc receptor blocker indicated for the treatment of: generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. ( 1.1 ) warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids. ( 1.2 ) 1.1 Generalized Myasthenia Gravis (gMG) IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. 1.2 Warm Autoimmune Hemolytic Anemia (wAIHA) IMAAVY is indicated for the treatment of warm autoimmune hemolytic anemia (wAIHA) in adult and pediatric patients 12 years of age and older currently or previously treated with corticosteroids.

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.